HomeCompareSRBCF vs PFE

SRBCF vs PFE: Dividend Comparison 2026

SRBCF yields 39215.69% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SRBCF wins by $4.252735580217355e+22M in total portfolio value
10 years
SRBCF
SRBCF
● Live price
39215.69%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.252735580217355e+22M
Annual income
$42,315,093,309,418,040,000,000,000,000.00
Full SRBCF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SRBCF vs PFE

📍 SRBCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRBCFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRBCF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRBCF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRBCF
Annual income on $10K today (after 15% tax)
$3,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$35,967,829,313,005,333,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SRBCF beats the other by $35,967,829,313,005,333,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRBCF + PFE for your $10,000?

SRBCF: 50%PFE: 50%
100% PFE50/50100% SRBCF
Portfolio after 10yr
$2.1263677901086776e+22M
Annual income
$21,157,546,654,709,020,000,000,000,000.00/yr
Blended yield
99.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SRBCF
No analyst data
Altman Z
-90.9
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRBCF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRBCFPFE
Forward yield39215.69%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.252735580217355e+22M$49.6K
Annual income after 10y$42,315,093,309,418,040,000,000,000,000.00$26,258.71
Total dividends collected$4.251340866571809e+22M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SRBCF vs PFE ($10,000, DRIP)

YearSRBCF PortfolioSRBCF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$3,932,269$3,921,568.63$9,153$693.39+$3.92MSRBCF
2$1,445,390,825$1,441,183,297.58$8,593$849.25+$1445.38MSRBCF
3$496,629,048,205$495,082,480,022.34$8,336$1,066.78+$496629.04MSRBCF
4$159,510,701,964,776$158,979,308,883,196.16$8,437$1,384.80+$159510701.96MSRBCF
5$47,892,225,784,148,210$47,721,549,333,045,900.00$9,013$1,875.40+$47892225784.14MSRBCF
6$13,442,027,069,357,296,000$13,390,782,387,768,257,000.00$10,306$2,680.72+$13442027069357.29MSRBCF
7$3,526,928,149,355,307,700,000$3,512,545,180,391,095,400,000.00$12,820$4,101.38+$3526928149355307.50MSRBCF
8$865,104,634,553,737,800,000,000$861,330,821,433,927,700,000,000.00$17,673$6,826.70+$865104634553737856.00MSRBCF
9$198,376,161,453,751,100,000,000,000$197,450,499,494,778,630,000,000,000.00$27,543$12,591.86+$198376161453751107584.00MSRBCF
10$42,527,355,802,173,560,000,000,000,000$42,315,093,309,418,040,000,000,000,000.00$49,560$26,258.71+$4.252735580217355e+22MSRBCF

SRBCF vs PFE: Complete Analysis 2026

SRBCFStock

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. Sirona Biochem Corp. has a research collaboration agreement with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop antiviral library of compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

Full SRBCF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SRBCF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRBCF vs SCHDSRBCF vs JEPISRBCF vs OSRBCF vs KOSRBCF vs MAINSRBCF vs JNJSRBCF vs MRKSRBCF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.